VSN16R

Canbex Therapeutics Ltd · Phase 2 active Small molecule

At a glance

Generic name	VSN16R
Also known as	Not yet available
Sponsor	Canbex Therapeutics Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VSN16R CI brief — competitive landscape report
VSN16R updates RSS · CI watch RSS
Canbex Therapeutics Ltd portfolio CI